VANCOUVER, British Columbia, March 27, 2017 /PRNewswire/ -- LightIntegra Technology Inc. today announced that its Board of Directors has appointed William “Bill” Dubiel as President and Chief Executive Officer effective March 13, 2017. Mr. Dubiel was also elected to the Board of Directors of LightIntegra. Paul Geyer will continue to serve as the Executive Chairman of LightIntegra.
“This is the perfect time for Bill to become LightIntegra’s next President and Chief Executive Officer. We’ve selected a very strong leader at a time when LightIntegra is ready to take the leap to commercialize the ThromboLUX product,” said LightIntegra’s Executive Chairman and departing CEO Paul Geyer. “Our next CEO needs to be an expert at commercially launching products into the market with early US focus while building a world class commercial organization with a heightened sense of urgency. Bill is unique in his ability to translate vision and strategy into world-class execution, building teams and driving high performance. His immediate focus will be on building a customer-centric sales organization and putting the systems and processes in place to commercialize our novel technology.”
Mr. Dubiel has more than 28 years of experience in the medical device industry and brings extensive commercial knowledge to the organization. He joins LightIntegra from Personal Genome Diagnostics, where he has been the Chief Commercial Officer. He has held senior level positions at CyVek, Ventana, Roche, Bayer and Chiron Diagnostics. He has led many commercial organizations and successfully launched 5 uniquely different disruptive technologies in the clinical and life science segment during his career.
“I am excited to lead LightIntegra at this pivotal time. LightIntegra has developed a unique testing system that improves quality of care, enhances productivity and lowers the cost of healthcare. These are the key ingredients of success in the healthcare market today and I am fortunate to lead a great team of people and bring this technology to healthcare providers and ultimately the patients they serve worldwide,” Mr. Dubiel said.
About LightIntegra Technology, Inc.
LightIntegra Technology is a privately funded medical diagnostics company and launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer. LightIntegra strives to minimize platelet refractoriness. To this end, LightIntegra created ThromboLUX, a rapid in vitro test that provides size distribution information for microparticles in blood products. As a routine test for platelet concentrates, ThromboLUX may identify which platelet units would be best suited for prophylaxis and which units are better suited for therapeutic use. Her years of research on platelet function led to a breakthrough discovery using dynamic light scattering to characterize platelets. Dr. Maurer recognized the opportunity to use this breakthrough - coupled with advances in laser and optics technology to address a market need to provide a safe, quick and simple diagnostic test for microparticles, platelet quality and function.
For more information about LightIntegra, please call us at 604.734.3548 or visit us on the web at www.lightintegra.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lightintegra-board-names-bill-dubiel-as-president--ceo-300429202.html
SOURCE LightIntegra Technology, Inc.
